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This study assessed the extent to which laboratory methods recommended by the Centers for Disease Control
and Prevention were used in tuberculosis testing of patients in California in 1998. While recommended
methods were used for most patients, there was room for improvement by hospital and independent non-health
maintenance organization laboratories.
The resurgence of drug-susceptible and multidrug-resistant
tuberculosis (MDR-TB) in the United States between 1985
and 1992 led to new recommendations that urged laboratories
to use more rapid and accurate testing methods for diagnosing
TB (2, 4). Studies assessing the use of recommended testing
methods for TB have consistently shown increases in the pro-
portion of laboratories adopting rapid methods (1, 3, 5, 6).
However, the extent to which laboratory-level improvements
correlate with improvements at the patient level is unknown.
TB testing services are gradually being consolidated in a small-
er number of laboratories; consequently, a few laboratories
using less rapid testing procedures now have the potential to
disproportionately affect the quality of testing for a large pro-
portion of TB patients.
In 1998, TB cases in California represented approximately
20% of all the TB cases in the United States (Centers for
Disease Control and Prevention [CDC], www.cdc.gov/nchstp
/tb/surv/surv.htm). That year, we conducted a study to assess
the use of recommended testing methods for California pa-
tients with culture-confirmed TB and to evaluate the testing
procedures of the mycobacteriology laboratories that per-
formed the tests for those patients.
Study population. The study population comprised 300 cul-
ture-confirmed cases of TB reported to the TB control pro-
grams in Los Angeles, Riverside, San Francisco, and Santa
Clara counties between 1 January and 31 December 1998. In
1998, 48% of California’s TB cases were reported in these
counties. We selected the first 75 culture-confirmed cases re-
ported in each county during the study period. Because only 68
cases were reported in Riverside County during 1998, 7 addi-
tional cases were selected from Los Angeles County. These
two counties are adjacent to each other and have similar pop-
ulations.
TB testing laboratories. Fifty-five separate laboratories were
identified through patient records as having performed pri-
mary TB testing for one or more of the study patients. If a
patient had many specimens tested for TB, the specimen with
the earliest test result was selected for this evaluation. The
laboratories that served the patient sample included 7 (13%)
public health laboratories, 2 (4%) health maintenance organi-
zation (HMO) laboratories, 11 (20%) independent non-HMO
laboratories, and 35 (64%) hospital laboratories. Laboratory-
specific calculations are based on 54 laboratories because
one hospital laboratory declined to participate in the study. In
addition to patient-specific data, each laboratory was asked to
complete a questionnaire concerning laboratory practices, in-
cluding the range of testing services performed and monthly
volume of specimens processed in that laboratory.
Completeness of data. Information on the testing method
used was available for 268 (89%) of the 300 patients for smear
microscopy, 265 (88%) of the 300 patients for mycobacterial
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TABLE 1. Proportion of laboratories performing TB testing,
compared with the proportion of TB patients tested
by these laboratories, by laboratory type
Test and group Total no.








Laboratories 44 3 (7) 8 (18) 2 (5) 31 (70)
Patients 268 54 (20) 39 (15) 39 (15) 136 (51)
Mycobacterial culture
Laboratories 43 4 (9) 8 (19) 2 (5) 29 (67)
Patients 265 58 (22) 38 (14) 39 (15) 130 (49)
Identification of
M. tuberculosis
Laboratories 27 5 (19) 9 (33) 2 (7) 11 (41)
Patients 272 83 (31) 61 (22) 40 (15) 88 (32)
Drug susceptibility
testing
Laboratories 19 6 (32) 8 (42) 1 (5) 4 (21)
Patients 266 99 (37) 82 (31) 23 (9) 62 (23)
1969
culture, 272 (91%) of the 300 patients for identification of
M. tuberculosis, and 266 (89%) of the 300 patients for drug
susceptibility testing. Unless otherwise noted, patient-specific
analyses are based on these denominators. Analyses were per-
formed using SAS 6.12 (SAS Institute, Cary, N.C.). If infor-
mation on a specific variable was missing for a laboratory or a
patient, the laboratory or patient was excluded from analyses
relating to that variable; for this reason, denominators for
different analyses may vary.
Comparison of laboratories performing TB testing and pa-
tient specimens tested by those laboratories. In some cases, a
small proportion of the laboratories was responsible for testing
a relatively large proportion of patient specimens for TB (Ta-
ble 1). Public health and HMO laboratories accounted for
,15% of the laboratories performing smear microscopy and
mycobacterial culture, but they tested more than one-third of
the patient specimens in our study population. Although most
(60 to 90%) laboratories performing TB testing were either
hospital or independent non-HMO laboratories, they per-
formed a relatively smaller proportion of testing. Even so,
these laboratories performed more than half of all TB testing.
Use of recommended testing methods. Most of the study
patients were tested using CDC recommended methods (Table
2). In general, the proportion of laboratories that performed
TB testing using recommended methods correlated closely
with the proportion of patients tested using those methods (Ta-
ble 3). However, differences in these proportions were noted
for smear microscopy, mycobacterial culture, and drug suscep-
tibility testing. With regard to smear microscopy and culture
testing, hospital laboratories largely accounted for these dis-
crepancies. For drug susceptibility testing in independent non-
HMO laboratories, the proportion of patients tested using
BACTEC was lower than the proportion of laboratories that
used this method. These differences suggest that laboratory-
level surveys may yield inaccurate estimates of the proportion
of patients tested using recommended methods.
Hospital laboratories that did not use recommended meth-
ods for TB testing generally processed a lower volume of spec-
imens (Table 4). Public health and HMO laboratories were
most likely to adhere to all of the recommended methods for
TB testing. These laboratories generally processed large vol-
umes of specimens for TB testing (.300 specimens per month
in most cases) and performed the full range of TB testing in
house.
Areas for improvement. Our results suggest that efforts to
further expand the use of recommended methods for smear
TABLE 2. Testing methods for smear microscopy, mycobacterial
culture, identification of M. tuberculosis and drug
susceptibility testing of patient specimens
Procedurea





Fluorochrome* .................................................................. 243 (91)
Carbol fuchsin.................................................................... 25 (9)
Mycobacterial culture medium
Liquid*................................................................................ 73 (28)
Solid .................................................................................... 17 (6)
Both*................................................................................... 175 (66)
Identification of M. tuberculosis
Nucleic acid probes*......................................................... 213 (78)
BACTEC NAP* ................................................................ 4 (1)
HPLC*................................................................................ 43 (16)
Biochemical tests ............................................................... 0 (0)
Nucleic acid amplification* .............................................. 12 (4)
Drug susceptibility
BACTEC* .......................................................................... 190 (71)
Agar proportion................................................................. 31 (12)
Both*................................................................................... 45 (17)
aMethods recommended by the CDC are indicated with an asterisk. BACTEC
was from Becton Dickinson, Sparks, Md. HPLC, high-performance liquid chro-
matography; NAP, p-nitro-a-acetylamino-b-hydroxypropiophenone.
TABLE 3. Proportion of laboratories using recommended methods for TB testing compared with the proportion
of patients tested using recommended methods by laboratory type
Test and group
No. with recommended method/total no. (%)
All laboratories
Laboratory type
Public health Independent non-HMO HMO Hospital
Fluorochrome staining
Laboratories 35/44 (80) 3/3 (100) 8/8 (100) 2/2 (100) 22/31 (71)
Patients 243/268 (91) 51/54 (94) 39/39 (100) 39/39 (100) 114/136 (84)
Liquid culture medium
Laboratories 37/43 (86) 4/4 (100) 8/8 (100) 2/2 (100) 23/29 (79)
Patients 248/265 (94) 58/58 (100) 38/38 (100) 39/39 (100) 113/130 (87)
Rapid identification of M. tuberculosisa
Laboratories 27/27 (100) 5/5 (100) 9/9 (100) 2/2 (100) 11/11 (100)
Patients 272/272 (100) 83/83 (100) 61/61 (100) 40/40 (100) 88/88 (100)
BACTEC drug susceptibilities
Laboratories 16/19 (84) 5/6 (83) 6/8 (75) 1/1 (100) 4/4 (100)
Patients 235/266 (88) 96/99 (97) 54/82 (66) 23/23 (100) 62/62 (100)
a Nucleic acid probe, BACTEC NAP, HPLC, or nucleic acid amplification test.
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microscopy and mycobacterial culture should focus on hospital
laboratories. Whereas other laboratories adhered to the use of
recommended methods for these tests, a large proportion of
hospital laboratories did not use a fluorochrome method for
the initial smear and/or liquid medium for mycobacterial cul-
ture.
Efforts to further expand the use of recommended methods
for drug susceptibility testing could focus on independent
non-HMO laboratories. In our study, a lower proportion of
patients in independent non-HMO laboratories was tested
using BACTEC compared with patients tested in other lab-
oratories. In California, the task of improving or monitoring
the adherence to recommended drug susceptibility testing
methods is facilitated by the relatively small number of labo-
ratories involved with this type of testing.
Study limitations. First, although the sample included 300
patients, testing for these patients was performed in a small
number of public health, HMO, and independent non-HMO
laboratories. Therefore, our results may not provide an accu-
rate portrayal of laboratory testing procedures. For example,
assessment of the role of specimen volume in the use of rec-
ommended testing methods for smear microscopy and culture
in hospital labs was limited by the small number of hospital
laboratories used in the analysis. However, our results do agree
with the results from previous studies showing that hospital
laboratories processing fewer specimens were less likely to use
recommended testing methods for smear microscopy and cul-
ture (6).
Second, data obtained from laboratories that tested a small
number of patients may not accurately describe the testing
practices in these laboratories. Some laboratories did not al-
ways use the same testing method for all specimens tested in
those laboratories. Therefore, it may not be appropriate to
assume a laboratory did or did not comply with recommended
testing practices based on data from a few patients.
Summary. Our findings suggest that most patients undergo-
ing evaluation for TB in California are tested using CDC-
recommended laboratory methods. These analyses also indi-
cate that results based on surveys at the laboratory level may
not accurately reflect results at the patient level. Future efforts
to expand the use of recommended methods for smear micros-
copy and mycobacterial culture should focus on low-volume
hospital laboratories, and for drug susceptibility testing the
focus should be on independent non-HMO laboratories.
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TABLE 4. Comparison of hospital laboratories using or not using
recommended testing methods for smear microscopy and
culture, by average monthly volume of specimens











Use of fluorochrome staining
for smear microscopy
Yes 17 4 (24) 5 (29) 8 (47) 1.73 (0.19)
No 9 4 (44) 3 (33) 2 (22)
Use of liquid culture
medium
Yes 18 4 (22) 5 (28) 9 (50) 2.33 (0.13)
No 6 3 (50) 2 (33) 1 (17)
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